Silexion Therapeutics Corp is a IL-based company operating in Biotechnology industry. Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The firm is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Follow-Up Questions
SLXN 股票的價格表現如何？
SLXN 的當前價格為 $3.73，在上個交易日 increased 了 3.35%。
Silexion Therapeutics Corp 的主要業務主題或行業是什麼？
Silexion Therapeutics Corp 屬於 Biotechnology 行業，該板塊是 Health Care
